OVERVIEW

Hexarelin is a synthetic growth hormone–releasing peptide (GHRP) that stimulates the secretion of growth hormone (GH) from the anterior pituitary gland. It acts by binding to the growth hormone secretagogue receptor (GHS-R1a), the same receptor activated by the natural hormone ghrelin. Due to its strong receptor affinity, Hexarelin is considered one of the more potent GHRPs in research settings. Studies have examined its effects on increasing circulating GH and insulin-like growth factor 1 (IGF-1) levels, which are associated with tissue repair, muscle development, and metabolic regulation. Because of its potency, it may also influence prolactin and cortisol levels, making careful dosing an important consideration in experimental protocols.

In addition to its endocrine effects, Hexarelin has been explored for potential cardiovascular benefits in preclinical research, with some studies suggesting protective effects on heart tissue under certain conditions. Its ability to promote anabolic signaling has led to interest in areas such as recovery, body composition, and age-related hormonal decline. However, as a research peptide, Hexarelin is not approved for general medical use in many regions and should only be handled within appropriate scientific or clinical frameworks. Ongoing research continues to evaluate its mechanisms, safety profile, and long-term physiological impact.